Information in Your Fingertips: Optimizing Vascular Health with PAT technologyItamar Medical News JournalSubscribe to Itamar Medical News Journal:
|
|||||||||||||||
|
About Itamar Medical News Journal
Itamar Medical Ltd., established in 1997, is a public medical technology company that developed the proprietary PAT™ (Peripheral Arterial Tone) signal technology and applications. The PAT signal is a non-invasive "window" to the cardiovascular system and the autonomic nervous system. Using this technology, Itamar Medical develops
noninvasive diagnostic systems, including the Watch-PAT™ systems for the diagnosis of sleep related breathing disorders and the Endo-PAT™ systems for assessment of endothelial function, a condition recognized as an early stage of cardiovascular and cerebrovascular diseases.
For further information see http://www.itamar-medical.com
ADD THIS FEED TO YOUR ONLINE NEWS READER
|
||||||||||||||
NavigateSponsorship & Advertising OpportunitiesFor exclusive sponsorship or advertising opportunities on this site please email advertise(at)sys-con.com, 201 802-3021. Exclusive sponsorship opportunities are available as an annual contract. 
UlitzerCopyright ©1994-2009 Ulitzer, Inc. All Rights Reserved. All marks are marks or trademarks of Ulitzer, Inc. Reproduction in whole or in part in any form or medium without express written permission of Ulitzer, Inc. is prohibited.
|
|||||||||||||||
Attunity Ltd. announced today that it has partnered with Open Text Corporation, an enterprise software company and a leader in enterprise content management, who will market advanced data connectivity solutions, including legacy decommissioning, data lifecycle management and real-time ...
Attunity
Ltd. (OTC BB: ATTUF.OB), a leading provider of real-time data integration and
event capture software, announced today a strategic partnership to market
solutions that enable real-time business intelligence and efficient data
integration based on the companies' data integra...
Attunity Ltd., introduces today a set of solutions based on a new concept coined 'Operational Data Replication' (ODR), which is designed to enable the large market of Oracle customers to replicate data in real-time to and from Oracle databases, at an affordable price point.
Itamar Medical announced the use of the company's patented Endo-PAT2000 in BioMarin Pharmaceutical Inc.'s phase 2 study of patients with Sickle Cell Disease (SCD). The Endo-PAT2000 was used to measure endothelial function in a study designed to evaluate whether the drug 6R-BH4 can impr...
Itamar Medical announced that it has received TGA clearance for the Endo-PAT2000, certifying the Endo-PAT2000 for use and distribution in Australia. Itamar Medical has developed the first simple, inexpensive, office-based diagnostic test for endothelial function. The Endo-PAT2000 is a ...
Itamar Medical announced its distribution agreement with EndoTech SPA to bring Itamar Medical's patented Endo-PAT2000, the first simple, office-based diagnostic test for the assessment of endothelial function, to the Italian market.
In the results of a new clinical study published by the Oxford Journal of Evidence-Based Complementary and Alternative Medicine, researchers find that supplementing your diet with flavonoids can reduce the acute decline in endothelial function caused by eating a high-fat meal.
In an effort to facilitate the process whereby patients receive the most up-to-date information, Answers Corp. and Itamar Medical will use the WikiAnswers Social Knowledge community platform for facilitating more efficient dialogue between doctors and patients. The companies will lever...
Subscribe to Itamar Medical News Journal Email News Alerts
Subscribe via RSS
Ulitzer content is offered under Creative Commons "Attribution Non-Commercial No Derivatives" License.
For any reuse or distribution, you must make clear to others the license terms of this work.
The best way to do this is with a link to this web page.
Any of the above conditions can be waived if you get written permission from Ulitzer, Inc., the copyright holder.
Nothing in this license impairs or restricts the author's moral rights.